CSL to Invest Approximately 1.5 Billion in U.S. to Manufacture Plasma-Derived Therapies
Summary
Global biopharma leader CSL announced plans to expand its U.S. presence over the next five years, resulting in approximately US $1.5B in U.S. capital investments, building on the company’s more than $3 billion U.S. investment since 2018, which created thousands of new jobs across 44 states.
November 18, 2025 — Global biopharma leader CSL announced plans to expand its U.S. presence over the next five years, resulting in approximately US $1.5 billion in U.S. capital investments. These investments will generate hundreds of high-quality American jobs, strengthen U.S. manufacturing capabilities of plasma- derived therapies (PDTs), and help secure the U.S. medicine supply chain. This reflects CSL’s commitment to meet the growing clinical need for immunoglobulin (Ig) over the long term.
“The U.S. is the world’s leading source for plasma, the main component of plasma derived therapies,” said Paul McKenzie, Chief Executive Officer and Managing Director, CSL. “These important medicines are often the most effective or only therapies available for many rare or serious diseases. By expanding our onshore production capacity in the U.S., we are deepening our commitment to patient care, creating high-quality jobs and driving innovation in the U.S.”
These planned investments are subject to approval by CSL’s Board of Directors.
Since 2018, CSL has invested over $3 billion into its U.S. operations, creating more than 6,500 new American jobs and bringing our total U.S. headcount to nearly 19,000, representing about 65% of CSL’s workforce.
CSL provides meaningful career opportunities for Americans nationwide from roles in manufacturing to scientific innovation. CSL’s plasma centers serve as an entry point into the healthcare sector, launching new careers and employing thousands of individuals across the country.